Morepen Laboratories is a pharmaceutical company built on a single, vertically integrated engine: it makes the active chemical ingredients inside medicines (APIs), turns them into finished tablets and capsules, and sells diagnostic devices and consumer health products directly to patients - all from its own factories in Baddi, Himachal Pradesh. Founded in 1984 and listed since 1992, the company nearly collapsed in 2003 when its blockbuster allergy drug Loratadine lost 89% of its price overnight, forcing a debt restructuring from which it emerged debt-free and profitable. The recurring approach that explains everything since is forward integration - capturing more value by moving from selling raw ingredients to other companies (30-40% value addition) into making the finished pills and consumer brands itself (60-70% value addition), while locking in recurring revenue wherever possible.
Business segments
Four engines built on one manufacturing backbone - a global API leadership platform, a finished-drugs business that captures the next margin, a locked-in diagnostics franchise with 17 million users, and a consumer health brand reaching over a lakh retail outlets.
1. API & CDMO: the chemical engine that funds everything else
Morepen is the world’s dominant supplier of three allergy and asthma drug ingredients, and it is now converting those transactional customer relationships into multi-year manufacturing contracts with predictable revenue.
- Market leader in six molecules - it holds 60-80% global market share in loratadine, desloratadine, and montelukast (allergy and asthma drugs), and roughly 30% in atorvastatin, rosuvastatin, and fexofenadine (cholesterol and allergy), with loratadine and montelukast alone contributing nearly half of API revenue.
- Export-heavy, hard-currency earnings - 72% of API sales go overseas to over 80 countries, with Europe, Asia, and the US as the largest destinations, so total American exposure is only about 7-8% of company revenue and the business earns in dollars and euros rather than competing solely on price in India.
- Capacity built ahead of demand - installed API capacity is 514 kiloliters with a mid-term target of roughly 800 KL, and the company deliberately keeps 20% of that as ready capacity to onboard new customers quickly, while also seeking outsourcing partners to handle overflow.
- Regulatory moat keeps out price-cutters - its factories are approved by the US FDA, European EDQM, Japanese, Brazilian, Chinese, and Korean regulators, with four consecutive USFDA inspections yielding zero observations; this lets it walk away from the purely price-driven Indian domestic market, where unapproved “garage companies” compete.
2. Finished formulations: capturing the next margin from its own ingredients
By turning its own APIs into branded prescription tablets and capsules, Morepen earns roughly twice the value addition compared to selling the raw powder to another manufacturer.
- Forward integration in action - selling API to a third party yields 30-40% value addition, but making the finished tablet and taking it to market yields 60-70%, so the formulations business is the natural margin-capture layer on top of the API engine.
- Three go-to-market channels - the business sells through branded prescriptions to doctors (Rx), supplies government and institutional tenders, and does contract manufacturing for other companies, though contract work is tiny at under 1% of total sales.
- Doubling the salesforce to reach more doctors - the company is expanding its medical representative count from 200 to 400 immediately, with a plan to reach 1,200 over three years, because the industry rule of thumb is roughly one crore rupees in revenue per MR.
- First-in-India bets from its own labs - it has filed for regulatory approval to launch resmetirom, a drug for fatty liver disease, where Morepen makes the API itself and is one of only two companies permitted to run bioequivalence studies; it has also developed over 30 new finished-dose products.
3. Medical devices: a locked-in diagnostics franchise with 17 million users
Morepen is India’s largest seller of glucometers and blood-pressure monitors, and it operates on a printer-cartridge model - the meter is nearly free, but the strips customers must buy every month work only on Morepen’s machines.
- The only fully integrated manufacturer in India - every step, from bare printed circuit boards and injection-moulded plastic bodies to final packing, happens in-house at Baddi, a backward-integration journey that began around 2015-2016 and gives it cost control no Indian rival can match.
- Annuity-like recurring revenue - 14.2 million glucometers have been installed with a lifetime free-replacement warranty, and each meter consumes roughly 150-180 test strips per year; in FY25 alone, 414 million strips were sold, and cumulative strip sales had crossed 1.5 billion by the prior year.
- BP monitors are scaling into viability - with 1.17 million units sold in FY25 and revenue up 14%, the blood-pressure monitor line has become an INR80-90 crore product, manufactured with full backward integration on dedicated production lines.
- Massive headroom in a vastly underdiagnosed country - India has roughly 212 million potential diabetic patients, of whom about 62% are undiagnosed; even against only the diagnosed population, Morepen’s 14 million installed meters leave a long runway.
- Capacity doubling to meet demand - glucometer capacity is rising from 25 lakh to 36 lakh units per year, strip capacity from 42 crore to 60 crore, and BP monitor capacity from 9 lakh to 18 lakh, with a new manufacturing block under construction.
4. OTC & consumer brands: the Dr. Morepen front door
Under the ‘Dr. Morepen’ brand, the company sells burn creams, cough syrups, pain relievers, sexual wellness products, and nutrition supplements directly to consumers through over a lakh retail outlets and online channels.
- A 75-year-old anchor brand - Burnol, the burn cream, is the heritage product, joined by Lemolate (cough and cold), Pain-X (pain management), EXYGRA (sexual wellness), and Fever-X (paracetamol), creating a basket of everyday health products that sit on the same retail shelves as the devices.
- Online is the growth channel - the online share of OTC sales increased from 5% to 16% in FY22, and a weight-loss product called LightLife was launched online-only, growing 30-40% month-on-month by combining a UK-sourced ingredient with Belgian probiotics.
- Distribution expanding state by state - direct retail reach grew from 80,000 outlets across 22 states to 1.10K outlets across 28 states, and the business has also started participating in government tenders.
- Housed in a separate listed subsidiary - the OTC business operates through Dr. Morepen Limited, which had revenues of roughly Rs. 171 crores in FY25, and the combined ‘Dr. Morepen’ brand umbrella - spanning devices, formulations, and OTC - had already crossed Rs. 685 crores in topline three years earlier.
Group structure and partners
The group is restructuring around a clean separation of its three engines - API manufacturing stays with the parent, while devices and formulations have been moved into dedicated subsidiaries, and the OTC business has been largely deconsolidated.
- API and manufacturing remain with the listed parent - Morepen Laboratories Ltd retains the core API and CDMO engine, along with a US subsidiary, Morepen Bio Inc., that markets bulk drugs in America and recently acquired a stake in a California biotech firm.
- Medical devices are being hived off into Morepen Medipath - after an earlier attempt to move devices into Morepen Devices Limited stalled, a new subsidiary, Morepen Medipath Limited (51% held by the parent), was created and a slump-sale agreement signed for roughly Rs. 181 crores; it has since set up a Dubai trading entity and a joint venture with a UAE partner for manufacturing.
- Formulations marketing sits in Morepen Rx - the distribution and marketing of finished-dose drugs was transferred to a wholly owned subsidiary, Morepen Rx Limited, so the parent can focus on manufacturing.
- The OTC business is now largely outside the consolidated group - Dr. Morepen Limited, which runs the consumer brands, was reduced from a 100% subsidiary to just under 20% ownership in July 2025, so its results are no longer consolidated and it is treated as an investment going forward.